The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the health and economic outcomes of emicizumab and valoctocogene roxaparvovec. All results related to valoctocogene roxaparvovec in the ICER review were considered highly preliminary given the FDA CRL determination. Here, we present the summary of our findings and highlight the policy discussion with key stakeholders held at a public meeting of the New England Comparative Effectiveness Public Advisory Council (CEPAC) on October 30, 2020. The detailed report is available on the ICER website: https://icer.org/wpcontent/uploads/2020/10/ICER_Hemophilia-A_Final-Report_112020.pdf.
